


3 January 2008

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclopharm

Nuclear Medicine



cyclomedica
molecularimaging
technegas

Cyclopharm Limited
ABN 74 116 931 250
Suite 630 Level 6
1 Queens Road
Melbourne Victoria 3004
Australia
T 61 3 9867 2811
F 61 3 9820 5957
www.cyclopharm.com

Cyclopharm achieves regulatory approval in Italy

Cyclopharm Limited (ASX: CYC) is delighted to announce it has received formal approval from the Italian regulatory authorities to register Technegas as an approved product in Italy.

In addition to achieving regulatory approval, Cyclopharm has appointed a new distributor in Italy and has agreed terms to sell 160 boxes into the Italian market and make 40 Technegas Plus generators available.

This represents a substantial expansion to the Technegas business in Europe.

There are more than 350 Nuclear Medicine sites in Italy and we are hopeful that Italy will very quickly become one of our largest markets in Europe. The potential exists for Italy to become a million dollar per year business. We are confident that our business in Italy will be highly successful and generate substantial returns.

Cyclopharm has been working with regulatory authorities in Italy for more than 18 months to register our products and we delighted with this milestone approval.

John Sharman
Managing Director

Contact details:

Mr John Sharman
Managing Director
Cyclopharm Limited
T +61 3 9867 2811

Mr William Richardson
Company Secretary
Cyclopharm Limited
T +61 3 9867 2811